Aspirin and clopidogrel resistance: methodological challenges and opportunities

Commentary

(2962) Views  (1521) Full article downloads

Author: Armen Yuri Gasparyan

Published Date March 2010 Volume 2010:6 Pages 109 - 112

DOI: http://dx.doi.org/10.2147/VHRM.S9087

Armen Yuri Gasparyan

Clinical Research Unit, Russell’s Hall Hospital, Dudley Group of Hospitals NHS Foundation Trust, West Midlands, UK

Abstract: Antiplatelet drug resistance is one of the urgent issues in current cardiovascular medicine. Many platelet function tests have been used to define responsiveness of patients with cardiovascular disease to aspirin and clopidogrel. In most studies, cut-off values of platelet function tests for defining responsiveness to antiplatelets were chosen arbitrarily. Different tests provided wide-ranging figures of the prevalence of aspirin and clopidogrel resistance, suggesting poor correlation between currently available platelet function tests. Measurement of platelet size seems to be a promising approach for monitoring antiplatelet drug therapy. This commentary highlights some limitations of studies on aspirin and clopidogrel resistance in patients undergoing coronary interventions.

Keywords: aspirin, clopidogrel, resistance, cardiovascular disease, platelet function tests